ERBB2 and gastric cancer: Despite the advances in diagnostic tools in GC, and the importance of targeted therapies, such as the human epidermal growth factor receptor (HER2) [13] and Epidermal Growth factor receptor (EGFR) that demonstrated improvements in overall survival in patients with advanced GC [14], the effects on mortality have been modest.